In spite of the developing endovascular era, large (15-25 mm) and giant (>25 mm) wide-neck cerebral aneurysms remained technically challenging. Intracranial flow-diverting stents (FDS) were developed to address these challenges by targeting aneurysm hemodynamics to promote aneurysm occlusion. In 2011, the first FDS approved for use in the United States market. Shortly thereafter, the Pipeline of Uncoilable or Failed Aneurysms (PUFS) study was published demonstrating high efficacy and a similar complication profile to other intracranial stents. The initial FDA instructions for use (IFU) limited its use to patients 22 years old or older with wide-necked large or giant aneurysms of the internal carotid artery (ICA) from the petrous segment to superior hypophyseal artery/ophthalmic segment. Expanded IFU was tested in the Prospective Study on Embolization of Intracranial Aneurysms with PipelineTM Embolization Device (PREMIER) trial. With further post-approval clinical data, the United States FDA expanded the IFU to include patients with small or medium, wide-necked saccular or fusiform aneurysms from the petrous ICA to the ICA terminus. However, IFU is more restrictive in South Korea than in United States. Several systematic reviews and meta-analyses have sought to evaluate the overall efficacy of FDS for the treatment of cerebral aneurysms and consistently identify FDS as an effective technique for the treatment of aneurysms broadly with complication rates similar to other traditional techniques. A growing body of literature has demonstrated high efficacy of FDS for small aneurysms; distal artery aneurysms; non-saccular aneurysms posterior circulation aneurysms and complication rates similar to traditional techniques. In the short interval since the Pipeline Embolization Device was first introduced, FDS has been firmly entrenched as a powerful tool in the endovascular armamentarium. As new FDS are developed, established FDS are refined, and delivery systems are improved the uses for FDS will only expand further. Researchers continue to work to optimize the mechanical characteristics of the FDS themselves, aiming to optimize deploy ability and efficacy. With expanded use for small to medium aneurysms and posterior circulation aneurysms, FDS technology is firmly entrenched as a powerful tool to treat challenging aneurysms, both primarily and as an adjunct to coil embolization. With the aforementioned advances, the ease of FDS deployment will improve and complication rates will be further minimized. This will only further establish FDS deployment as a key strategy in the treatment of cerebral aneurysms.
DEVELOPMENT OF FLOW-DIVERTING STENTS (FDS)
Following development of the detachable microcoil by Guido Guglielmi in the early 1990s and its subsequent United States Food and Drug Administration (FDA) approval in 1995, endovascular coil embolization of cerebral aneurysms spread throughout the world [49] [50] [51] . Adoption of Guglielmi microcoil embolization represented a paradigm shift in the neurosurgical treatment of cerebral aneurysms. As endovascular technique evolved, limitations to primary coil embolization spurred parallel development of additional endovascular devices to facilitate treatment of aneurysms not amenable to primary coil embolization. Chief among these were balloon and intracranial stent-assisted techniques that expanded indications for endovascular treatment of cerebral aneurysms 59) . Despite the development of an entire industry of endovascular microcoil systems; liquid embolic agents; balloon catheters; and intracranial stents to aid coil embolization, large (15-25 mm) and giant (>25 mm) wide-neck cerebral aneurysms remained technically challenging 81, 83, 105) . Obliteration rates were low and recurrence rates were high following endovascular treatment of these challenging lesions 39) . The combination of unsatisfactory results with attempted endovascular techniques and high morbidity with open treatment highlighted the need for a novel solution to treat the most challenging of cerebral aneurysms 31) . Early series sought to push the boundaries of stent-assisted coil embolization techniques to achieve more satisfactory clinical and radiographic outcomes 11, 105) . Traditional intracranial stents were designed to facilitate coil embolization. These stents have low metal surface-area coverage and high porosity to maintain both parent vessel and branch vessel patency. Additionally, these stents serve as a buttress supporting the coil mass and were designed with high radial force. While these characteristics support a coil mass, traditional stents remain vulnerable to coil prolapse and technically challenging to deploy across significant curves or tortuous segments. Unfortunately, unacceptably high recurrence rates persisted 11, 105) . Intracranial FDS were developed to address these challenges by targeting aneurysm hemodynamics to promote aneurysm occlusion-a significant departure from traditional intracranial stent design. This design innovation meant FDS were developed as a single-stent treatment solution for intracranial aneurysms not amenable to traditional coiling and assistedcoiling techniques 8, 15, 85, 101, 119) . To achieve this goal, FDS eschewed high radial force designs to buttress coils in favor of low radial force to promote conformability and navigability in tortuous vessels. Additionally, FDS were woven with increased metal surface-area coverage to promote flow along the parent vessel and decrease flow into the aneurysm while maintaining sufficient porosity to maintain branch vessel and perforator patency. FDS promote aneurysm occlusion by three major mechanisms. First, FDS decrease direct jet blood flow into the aneurysm and promotes laminar flow along the stent in the direction of the parent artery, so-called central diversion 24) . Next, this central diversion decreases the speed of blood flow within the aneurysm; increases stagnation; and promotes intra-aneurysmal thrombosis. This decreased wall stress and stagnant flow results in aneurysm remodeling that ultimately promotes endothelialization across the aneurysm neck and arterial reconstruction 24, 42, 98, 102) . The Pipeline Embolization Device (PED) (Medtronic, Irvine, CA, USA) was granted FDA approval in 2011, the first FDS approved for use in the United States market 114) . Shortly thereafter, the Pipeline of Uncoilable or Failed Aneurysms (PUFS) study was published demonstrating high efficacy and a similar complication profile to other intracranial stents 3, 5) . The initial FDA instructions for use (IFU) were limited to adult patients with the wide-neck, large or giant aneurysms between the petrous and ophthalmic segments of the internal carotid artery (ICA) 114) . With published reports of safe off label use for aneurysms beyond the petrous to ophthalmic ICA and development of second generation FDS, the IFU has since expanded to small (<7 mm) and medium (7-15 mm), wide neck aneurysms of the entire intracranial ICA. To date, safe off-label use has been reported for cerebral aneurysms in most cerebrovascular territories with a parent vessel diameter of 2-5 mm 6, 9, 10, 16, 18, 21, 26, 47, 73, 94, 107, 120, 121) .
CHARACTERISTICS OF FDS
As the world's first FDS, the PED has the greatest volume of utilization data in the peer-reviewed literature. The second generation PED, Pipeline Flex Embolization Device (PFED) (Medtronic), was introduced in 2015 and achieved independent FDA approval in 2018. The PFED has now surpassed the . The Surpass FDS received initial FDA approval in 2018 and post-approval clinical evaluation is currently ongoing with the Surpass Intracranial Aneurysm Embolization System Pivotal trial (SCENT) in large or giant wide-necked aneurysms at 23 centers is the United States 80) . With the exception of the PED/ PFED and Surpass (FDA approved in 2018) 115) , other FDS are either not available in United States or actively in the approval process. However, PED/PFED, Surpass, and FRED are approved for use in South Korea.
IFU in United States and South Korea
The FDA granted initial approval of the PED in 2011 18, 21, 98) . The initial FDA IFU limited its use to patients 22 years old or older with wide-necked large or giant aneurysms of the ICA from the petrous segment to superior hypophyseal artery/ ophthalmic segment 114) . Following approval, many practitioners published series reporting PED safety and efficacy in the off-label treatment of aneurysms that did not meet the widenecked or large, giant aneurysm criteria 89) . With further postapproval clinical data the FDA expanded the IFU to include patients with small or medium, wide-necked (neck ≥4 mm or dome : neck <2) saccular or fusiform aneurysms from the petrous ICA to the ICA terminus 116) . Expanded IFU were tested in the Prospective Study on Embolization of Intracranial Aneurysms with Pipeline TM Embolization Device (PREMIER) trial 53) . Twenty-two clinical centers participated in the PRE-MIER trail and enrolled 141 cases of small-medium (≤12 mm), wide-necked ICA aneurysms. The complete occlusion rate (Raymond grade I) was 76.8% at 12 months with a 30-day major neurologic morbidity rate (major ipsilateral stroke or neurologic death) of 2.1%. PREMIER trial further validated clinical series of safe off-label use.
Although the PED has been approved for use in South Korea since 2014 54) , IFU are more restrictive in South Korea than in United States. Korea IFU limited its use to patients with only unruptured aneurysm. Aneurysmal diameters have to be over 15 mm. If aneurysmal diameter is less than 15 mm, some requirements have to be fulfilled for FDS use as follows : blister aneurysm on proximal ICA, fusiform aneurysm, or dissecting aneurysm on vertebral artery. FDS is allowed during procedure only one. If FDS are used during procedure multiple unavoidably, Heath Insurance Review and Assessment (HIRA) Service carry out inspections of medical rationale 62) . Moreover, use of any detachable coil jointly is not allowed with FDS. Korean neurosurgeons expect Korea IFU of FDS to be changed because PREMIER trial validated clinical series of safe expanded indications and FDA approved of expanding the IFU in United States.
Profiles of FDS
The PED is a self-expanding, microcatheter guidewire-delivered, braided mesh cylinder constructed of 48 interwoven stands of platinum-tungsten and cobalt-chromium-nickel alloy wire. This design results in 30-35% metal coverage of the arterial wall surface area. The device is available in diameters from 2.5-5.0 mm with a deployed diameter up to 0.25 mm larger than the labelled diameter and lengths of 10-35 mm 43, 74) . There are not integral radiopaque markers on the PED. Rather, the delivery micro-guidewire has a 15 mm soft distal tip preceded by a distal radiopaque marker as well as both radiopaque resheathing ("point of no return") and proximal markers. The 2nd generation PFED did not see significant changes to the basic design but did involve substantial revisions to improve the delivery system. These changes made the PFED easier to deliver, particularly around tortuous segments, and easier to resheath 76, 78, 90) . The Surpass Streamline FDS was also designed as a low-porosity mesh tubular structure. In contrast to the PED/PFED, it is composed of cobalt-chromium alloy wires with interwoven radiopaque platinum-tungsten wires for radiopacity integral to the stent. The 3-and 4-mm Surpass FDS are composed of 72 wires compared to 96 wires in the 5-mm Surpass FDS. Increased mesh density increased metal coverage thereby decreasing aneurysm blood flow and producing a more uniform rhomboidal cell density as vessels taper 27, 34) . Additionally, the Surpass FDS is available in lengths up to 50 mm to reduce the need for multiple devices to cover lesions and the inherent risks associated with the use of multiple overlapping or telescoping FDS. The Surpass FD is unique in that it is preloaded at the distal end of 0.040 inch inner diameter delivery microcatheter 112) . FRED is unique in that it is composed of a two-layered weave. The 16-strand outer layer functions similar to a tradi-https://doi.org/10.3340/jkns.2020.0034 tional low metal coverage stent while the 48-strand inner nitinol layer functions as a FDS. The stent has several integral radiopaque markers with four markers on each end of the outer stent and two interwoven helical radiopaque wires between the inner and outer layer. FRED is available in diameters from 3.5-5.0 mm and lengths from 13-55 mm. Due to a 5 mm overhang of the outer vs. inner layer, the FRED achieves slightly shorter working lengths. This design was theorized to improve both navigability and wall apposition to aid complete aneurysm occlusion, particularly in tortuous parent vessels 38, 64, 75) . In an initial series of 34 large or giant wide necked aneurysms in 29 patients, 3-and 6-month complete aneurysm occlusion rates were 56% (n=34) and 73% (n=30), respectively 81) .
GENERAL PROCEDURES
Preparation for a FDS procedure is very similar to conventional coil embolization or stent-assisted coil embolization techniques for cerebral aneurysms. Differences in technique arise from the larger profile of FDS that necessitates planning for larger guide and intermediate catheters with emphasis on greater proximal support than traditional coil embolization techniques 27, 29) . In general, a large diameter 6-or 7-French (F) guide catheter or shuttle sheath is used proximally in the common carotid artery or ICA. An intermediate support catheter of 5-6 F is often used for added support 29, 69) . The microcatheter (0.027 inch inner-diameter) will be navigated past the aneurysm over a microwire with the microcatheter left distal to the target aneurysm. Next, the microwire is removed and the FDS is loaded into the microcatheter. Vessel tortuosity and curves make FDS susceptible to the Simmons effect, or paradoxical movement of the catheter. Greater vessel tortuosity lends to greater Simmons effect. This can result in the microcatheter jumping or migrating during FDS delivery. For this reason, we recommend preliminarily deploying the distal portion of stent until the cells fully expand 20 mm or more distal to the aneurysmal neck. This is usually accomplished by exposing 10-15 mm of the FDS 64, 70) . The Surpass FDS is preloaded in a 3.7 F microcatheter, unique versus other systems 34) . The intermediate catheter must pass across the parent artery of aneurysm neck portion for surpass deployment to facilitate ease of deployment. For all other FDS, once distal FDS is deployed and expanding the microcatheter is drawn back to the predetermined distal landing position.
After this maneuver, FDS deployment can proceed by unsheathing the stent. To do so, the FDS delivery wire is held with slight forward tension while the microcatheter is drawn back. The practitioner can "push" the FDS to promote further expansion and deployment once the FDS distal marker aligns with the distal microcatheter tip. Successful FDS deployment requires a balance between pushing delivery-wire and unsheathing microcatheter from the device. In general, it is ideal that the proximal or "unsheathing" FDS be shaped like a wine glass. Insufficient forward-loading or aggressive unsheathing can result in cells expanding in the shape of a champagne flute. In contrast, excessive forward loading of the FDS will result in the expanding FDS cells taking the shape of a martini glass (Fig. 1 ). Both configurations can be avoided by monitoring cell expansion real time with live fluoroscopy. Good wall apposition is key to successful FDS deployment. However, in many cases this can be difficult to achieve. If insufficient apposition is identified, the push-pull technique can be used to improve deployment against the vessel wall ( Fig. 2) . After completely deploying the FDS, wall apposition is confirmed by angiography. If wall apposition is insufficient, the practitioner can use conformable intracranial balloons to remodel the stent with good vessel apposition 28,33) ( Fig. 3 ).
PERIPROCEDURAL ANTIPLATELET TREAT-MENT
FDS procedures are susceptible to a variety of thromboembolic complications. As such, pre-and post-procedure dual antiplatelet therapy (DAPT) is considered the standard of care for all FDS procedures 7, 35, 40, 113) . Direct injury of arterial endothelium during FDS deployment can activate the extrinsic pathway and led to intra-or post-procedural thrombosis. Following FDS deployment, altered flow dynamics will persist until neo-endothelialization such that the vessel is at risk of thrombosis at any time up until the stent is fully endothelialized or "healed in" 36)
. Moreover, changes in flow direction, speed, and turbulence are very difficult to predict. In-stent thrombosis or distal embolization can lead to ischemic stroke that ranges from clinically silent to permanent neurologic deficit or death, depending on the arterial territory involved. While the use of DAPT is widely accepted, a variety of dosing regimens exist pre-and post-procedure. A typical protocol would be aspirin 81-325 mg and clopidogrel 75 mg for 5-7 days pre-procedure with or without a loading dose of clopidogrel 1) . The post-procedural duration of DAPT also is not standardized. Generally, clopidogrel 75 mg is continued for 3-6 months and aspirin 81-325 mg is continued for a minimum of 6 months 113) . Clopidogrel resistance is associated with thromboembolic complications in both the cardiac and neuroendovascular literature such that many practitioners use platelet function assays to assess the DAPT response 40) . In patients not responsive to clopidogrel 75 mg daily, increasing the dose, or a switch to ticagrelor is often employed 67) . Further research is needed to determine an evidence-based "best" protocol for pre-and post-rpocedure DAPT in FDS deployment and neuroendovascular therapy more broadly.
EFFICACY OF FDS BY ANEURYSM TYPE

Overall efficacy of FDS
Several systematic reviews and meta-analyses have sought to evaluate the overall efficacy of FDS for the treatment of cerebral aneurysms. Three large studies reported largely similar results. In 2013, Brinjikji et al. 14) reported a meta-analysis of 29 studies representing 1451 patients treated with FDS and found complete occlusion, morbidity and mortality rates of 76%, 5%, and 4%, respectively. Arrese et al. 2) analyzed an ad- 
Wide-necked, large and giant aneurysms
The original indication for the various FDS was widenecked, large or giant aneurysms of the ICA. While the indications for FDS have expanded beyond this original IFU and the use of FDS with traditional coiling techniques has grown, the most developed evidence for FDS efficacy is in this original group of aneurysms 89) . The PUFS trial is perhaps the most well-known 4) . PUFS included 180-day follow up of patients undergoing PED deployment PED for unruptured cerebral aneurysms meeting the original FDA IFU. The trial prospectively enrolled 108 patients over an 8-month period at 10 United States centers. PED were successfully deployed in 99.1% of patients. Monotherapy with the PED resulted in complete occlusion (Raymond I) in 73.8%, 86.8%, and 92.1% at 6-, 12-, and 36-month angiographic follow-up, respectively with a 5.6% 180-day major complication rate. Moreover, 97.4% of treated vessels were free of significant (>50%) stenosis at 3 years angiographic follow-up and there were no additional instances of intracranial hemorrhage between 1 month and 3 years 5) . The late complication rate at 5-year follow up was 0% 3) . Success of the PUFS trial and its subsequent longterm follow up was a paradigm shift aneurysms treatment. The trial not only validated a novel device, the FDS, but also validated an effective treatment for wide-necked large and giant aneurysm that had been so challenging to treat prior to PUFS 46, 48, 117) . In a similar study, Chalouhi et al. 20) compared FDS (40 cases) and coiling (120 cases) for treatment of large (>10 mm) unruptured intracranial saccular aneurysm. While there was no significant difference in complication rates (7.5% vs. 7.5%), the FDS group had significantly higher rates of complete aneurysm occlusion on angiographic follow up, 86% vs. 41% (p<0.001). Good efficacy of FD in large aneurysm can found other studies. In an evaluation of large cavernous carotid aneurysms, Tanweer et al. 111) reported 88.4% 2-year Raymond I occlusion and 100% Raymond I or II occlusion at 3-year follow up. In the treatment of cavernous carotid aneurysms there was a 2.3% major neurologic complication rate and 0 patient deaths. In a slight variation, Chiu et al. 23) investigated the efficacy of PED for aneurysms not amenable to coil embolization, defined as neck : >4 mm; dome/neck ratio <1.6; fusiform morphology; and/or size >10 mm. At 2-year angiographic follow up 93.2% of aneurysms were completely occluded. Their series reported minor complications in 7.6% (4.2% transient ischemic attacks; 3.4% minor stroke) and major complications in 1.6% (0.8% major stroke; 0.8% mortality 23) . In a similar study, Kim et al. 60) reported 77.4% complete occlusion rate at 2-years for large/giant (>15 mm) intracranial aneurysms undergoing FDS placement. They reported a 4.4% procedural morbidity rate and no mortality.
Small and medium-sized aneurysms
Building on promising data in challenging wide-necked large or giant aneurysms, reports of off-label FDS use for smaller aneurysms not amenable to coil embolization followed. In a multicenter study of 149 small (<7 mm) unruptured intracranial aneurysms, Griessenauer et al. 47 
Distal artery aneurysms
Reports of off-label FDS use have included several reports involving distal artery cerebral aneurysms. As the smallest PED/PFED diameter is 2.5 mm and the smallest Surpass FDS diameter is 3 mm, the current compliment of FDA-approved FDS generally are not suited to the treatment of distal aneurysms. In addition to restrictive parent vessel diameters, distal arteries are often tortuous and may have more small branches 73, 84) . Taken together, these anatomic properties of distal arteries increase the technical demands to deploy the FDS; risk of failed deployment; and risk of complications. Early in the clinical use of FDS, Pistocchi et al. 94) reported their experience with FDS in 26 patients with aneurysms of the anterior circulation distal to the ICA terminus. The complete occlusion rate was 82.6% and permanent neurological complications occurred in 3.7%. Several more recent series of <30 cases similarly reported complete occlusion rates of 75-80% and complication rates of 3.7-13% 9, 16) . In a study focusing on FDS for the treatment of 50 anterior communicating artery complex aneurysms, Colby et al. 26) reported complete occlusion rate of 86% and a complication rate of 6%. For comparison, Sturiale et al. 109) reported 20 cases of traditional stent-assisted coil embolization of distal anterior cerebral artery (ACA) aneurysms and experienced a 20% complication rate. A recent metaanalysis of coil embolization techniques for distal ACA aneurysms reported morbidity and mortality of 15% and 9%, respectively 92) . The recent development of low-profile braided FDS and additional design advances in FDS and their delivery systems my make distal artery aneurysm more amenable to this promising technique 82) .
Non-saccular and posterior circulation aneurysms
Despite advances in both open and endovascular surgical technique, non-saccular fusiform or dissecting aneurysms and posterior circulation aneurysms have remained challenging lesions. The complete occlusion rates for these lesions are lower necessitating frequent staged or revision treatment. And, the complication rates have remained high despite new techniques 46, 55, 104, 108) . With the advent of FDS and reports of their efficacy in complex ICA lesions, there was natural excitement at the prospect of apply FDS to the treatment of these challenging aneurysms. In a 2015 meta-analysis, Rouchaud et al. 99) 6) achieved 78% complete occlusion using FDS for posterior circulation aneurysms with a 9% complication rate. These results were somewhat at odds with contemporary case series, but the authors attributed their improved results to a preponderance of posterior circulation aneurysms isolated to the vertebral artery in their series 6) . While efficacy may have been less than traditional techniques, FDS was often associate with a relatively lower complication rate for posterior circulation aneurysms. Given the lower occlusion rates. Further advances in FDS as well improved facility with FDS-assisted coiling and overlapping FDS techniques may facilitate improved obliteration rates, but further clinical data is needed before a revision of IFU to include posterior circulation aneurysms would likely be considered.
COMPARISON OF TECHNIQUES FOR THE ENDO-VASCULAR TREATMENT OF CEREBRAL ANEU-RYSMS
Coil embolization vs. FDS
With the expansion of FDS use beyond the large and giant wide-necked aneurysms of the ICA not amenable to coil embolization, a comparison can now be made between traditional coil embolization and FDS for treatment of cerebral aneurysms. Petr et al. 91 
FDS vs. FDS-assisted coil embolization (FDS-CE)
While FDS and traditional stents are grossly similar, the modulation of aneurysm flow dynamics adds an additional property to facilitate aneurysm occlusion in stent-assisted coiling techniques 56) . Lin et al. 72) compared outcomes for FDS alone and FDS-CE for 104 aneurysms. In their institution, the coils are used as a scaffold to buttress the aneurysm dome and occlusion is reliant on aneurysm flow modulation by the FDS. This is in contrast to the dense packing needed in primary coil embolization techniques. 
Single FDS vs. multiple overlapping or telescoping FDS
Most FDS have metal surface area coverage similar to the PED/PFED, or 30-35% in typical clinical applications. Theoretically, the use of multiple overlapping FDS would result in higher metal surface area coverage and further restriction of aneurysm blood flow, thereby increasing intra-aneurysmal thrombosis and occlusion. However, deployment of multiple overlapping FDS increases the number of endovascular manipulations and would lead to higher risk of complications. Chalouhi et al. 19) 19 ) the multiple FDS group included more high-risk patients; a higher median patient age; larger mean aneurysm size; more posterior circulation and distal circulation aneurysms; and more non-saccular aneurysms. All of these factors have been associated with higher complication rates. Additionally, 11% of single FDS and 6% of multiple FDS patients underwent adjunctive coiling of the aneurysm. In comparison, Kabbasch's study excluded aneurysms that had either been previously treated with coiling or that underwent adjunctive coil embolization, treatment aneurysm and adjunctive coil cases 57) . These differences in confounding risk factors may explain the conflicting results 19) . Taken together, these studies suggest the multiple FDS technique may improve occlusion in complex aneurysms but must be weighed against likely higher complication rates.
COMPLICATIONS IN ANEURYSMS TREATED WITH FDS
As previously outlined, the complication rates for aneurysms treated with FDS are comparable to traditional coil embolization in both individual series and head-to-head comparison. Furthermore, it is often the case that FDS in these series may be used to treat aneurysms of higher complexity, with higher proportions of independent risk factors for complications 2, 12, 14) . Several studies have detailed the complications encountered when FDS were used to treat aneurysms in detail. In their meta-analysis published in 2017, Zhou et al. 122) analyzed 60 studies comprised of 3125 patients treated with FDS. The overall complication rate was 17.0%. Complications were significantly higher when FDS were used to treat ruptured aneurysms (30.6% ruptured vs. 14.6% unruptured, p<0.05). When comparing anterior and posterior circulation aneurysms treated with FDS, the complication rate for posterior circulation aneurysms was significantly higher (44.7%). Lin et al. 71) analyzed ruptured aneurysms treated with FDS at multiple United States centers. While they found a complete occlusion rate of 78.3%, the procedural complication rate was 19.2% and 11.2% of patients were deceased at hospital discharge. The IntrePED trial included long-term follow up with neurologic morbidity and mortality rate of 8.4%. In their sub-group analysis of morbidity and mortality by aneurysm size and location, anterior circulation aneurysms <10 mm had the lowest risk (4.8%) while posterior circulation aneurysms had the highest complication rates (16.4%) 58) . Brinjikji et al. 13) also evaluated this IntrePED dataset, focusing on ischemic complications following FDS use. Ischemic complications were significantly higher with aneurysms of the middle cerebral artery territory; fusiform aneurysms; and giant aneurysms (>25 mm). Aneurysm neck diameter was also found to be significantly larger in the subgroup with ischemic complications. While many studies focused on immediate perioperative complications of FDS use, Cohen et al. 25) sought to characterize delayed complications after FDS for treatment of intracranial aneurysms. Progressive in-stent stenosis was documented in 36%, of which only 15% were symptomatic, and was identified as early as 2 months post-procedure. Vedantam et al. 118) reported on carotid branch occlusion following FDS deployment in 49 patients. Three patients were found to have ICA branch occlusion and were asymptomatic in all cases. Furthermore, the number of FDS deployed was not significantly associated with in-stent stenosis; branch vessels occlusion; visual symptoms or motor deficits. They also found that symptomatic ischemic complications were more common in the 30-day immediately following FDS placement; this led the authors to hypothesize that gradual branch occlusion was compensated by adequate existing or neo-collateral circulation. Ischemic complications in the posterior circulation are more often symptomatic due to the smaller parent vessel diameter and relatively dense perforating artery supply arising from these vessels compared to the anterior circulation. Parent artery occlusion is a well-documented and dreaded complication of FDS deployment 22, 66, 87, 96, 97) . Asymptomatic parent vessel occlusion is frequently associated with anterior circulation aneurysms 94) . In contrast, parent artery occlusion in the posterior circulation is often associated with significant morbidity and/or mortality 95) . A common theme across studies is the association of parent artery occlusion or in-stent stenosis with discontinuation of antiplatelet agents 6, 10, 41, 63, 79) . Accordingly, FDS demands strict attention to DAPT and screening for clopidogrel non-responders -platelet function testing can be a meaningful adjunct in the later task 40) . Thoughtful planning and monitoring of DAPT is of particular importance in posterior circulation FDS cases. Tan et al. 110) found that among 74 patients treated with FDS, P2Y12 reaction units (PRU) >208 was associated with higher rates symptomatic stroke, though the difference was non-significant. Delgado Almandoz et al. 36 ) similarly reported that under-response to clopidogrel was associated with increased symptomatic stroke after FDS deployment. On the other hand, hyper-responsiveness to clopidogrel by PRU was associated with higher rates of spontaneous hemorrhage in Goh et al. 45) and the rates of spontaneous hemorrhage were concordant with Delgado Almandoz et al.
36)
. The major complications of FDS deployment include symptomatic ipsilateral ischemic stroke; intraparenchymal hemorrhage; and peri-procedural subarachnoid hemorrhage (SAH) secondary to aneurysm rupture 32) . Early in FDS development particular emphasis was placed on periprocedural SAH due to the independent morbidity and mortality of SAH. One large meta-analysis in 2013 found 4% of early PED cases were complicated by delayed SAH and this was significantly associated with large or giant aneurysms. Late delayed aneurysm rupture (>1-month post procedure) was rare, representing only 2% of postprocedural SAH 14) . Rouchaud et al. 100) reviewed 53 studies of FDS placement to identify 81 cases of delayed hemorrhage. Aneurysms were located on the ICA in 75% and 46.3% of cases were giant aneurysms. These findings may be confounded by the IFU for PED/PFED that selects for large or giant anterior circulation aneurysms, predominantly of the ICA. The mechanisms of delayed hemorrhage remain unclear. Several hypotheses have been put forward, including transiently increased intra-aneurysmal pressure during or following FDS implantation 17) ; thrombus-associated autolysis of the aneurysm wall 17, 65) ; increased hemodynamic strain on the aneurysm wall directly 24) . Using computational hemodynamic analysis, Chong et al. 24) demonstrated significantly decreased jet flow through the aneurysm sac with marked stasis at the periphery of the aneurysm. Flow observation was increasingly difficult overtime consistent with progressive aneurysm thrombosis. In unsuccessful cases, however, jet flow pattern was unchanged by FDS deployment and may persist into the aneurysm. After considering these factors, several techniques have been advocated to avoid periprocedural aneurysm rupture, including adjunctive coil embolization and strict blood pressure control perioperatively 68) . 
FUTURE DIRECTIONS FOR FDS
In the short interval since the PED was first introduced, FDS have been firmly entrenched as a powerful tool in the endovascular armamentarium. The IFU have been broadened and off-label use has systematically progressed to nearly all large vessel territories of the cerebrovascular circulation. As new FDS are developed, established FDS are refined, and delivery systems are improved the uses for FDS will only expand further. Researchers continue to work to optimize the mechanical characteristics of the FDS themselves, aiming to optimize deploy ability and efficacy. Recent advances like duallayered weave and new cell configurations target improved wall apposition, more uniform cell configuration, improved and uniform radial force, and improved delivery and resheathing. The FRED Jr (Microvention, Tustin, CA, USA) was recently introduced specifically to address the challenges of using FDS in small distal arteries 82, 93) . While it retains the dual-layered construction of its namesake, it leverages a 36-wire inner layer and 16-wire outer layer to facilitate use in vessels from 2-3 mm in diameter. Increased attention to DAPT and pooling of data will help to develop more rigorous guidelines for pre-and post-procedure DAPT while quantitative screening for non-responders with platelet function and clotting assays will guide personalized DAPT regimens for the individual patient. Additionally, new techniques to combat thrombosis may further reduce ischemic complications. For example, phosphorylcholine-a component of erythrocyte outer cell membrane-may resist platelet adhesion and promote intimal hyperplasia. These properties have been leveraged in Shield Technology TM (Medtronic) whereby a 3 nm layer of phosphorylcholine is covalently bound to the PED weave surface. In pre-clinical studies PED shield has been associated with reduced inf lammation, reduced thrombosis, and increased early neointimal growth 44, 52, 77) . Finally, further data on the safety of FDS and DAPT in acutely ruptured aneurysms is needed to inform further use in this sub-population of aneurysm patients. Surpass Evolve (Stryker Neurovascular) is the second generation of Surpass Streamline FDS. It has 52 wires made of cobalt-chromium and 12 wires made of platinumtungsten for fluoroscopic visibility 103) . Surpass Evolve has fewer wires and the different braid angle compare to Surpass Streamline. These changes improve flexibility and wall apposition. The improved flexibility may enhance deliverability of the stent through the microcatheter. Surpass Streamline has a medium braid angle whereas Surpass Evolve has a higher braid angle. The higher braid angle is one of the important factors to improving vessel wall apposition. Despite Surpass Evolve having fewer wires, high braid angle maintains the same mesh density (pores per mm 2 ) as Surpass Streamline. However, high braid angle may lead to more stent foreshortening then medium braid angle.
With expanded use for small to medium aneurysms and posterior circulation aneurysms, FDS technology is firmly entrenched as a powerful tool to treat challenging aneurysms, both primarily and as an adjunct to coil embolization. With the aforementioned advances, the ease of FDS deployment will improve and complication rates will be further minimized. This will only further establish FDS deployment as a key strategy in the treatment of cerebral aneurysms.
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